



Antimicrobial Resistance (AMR) in Japan, Present, Past Fact and Next Strategy under COVID-19 Pandemic

Guest Editor:

Dr. Ken Kikuchi

Department of Infectious
Diseases, Tokyo Women's
Medical University, Tokyo, Japan

Deadline for manuscript
submissions:

closed (1 September 2021)

Message from the Guest Editor

Dear Colleagues,

Antimicrobial resistance (AMR) is one of the most common medical problems in the world and AMR organisms could cause up to 10 million deaths in 2050. In Japan, the AMR action plan has been proposed since 2016 according to WHO recommendation, but the past and current status and the strategy was not recognized enough. For example, methicillin-resistance is still highly frequent (30-50% of *Staphylococcus aureus*), but vancomycin-resistance is rarely isolated (<0.1% of *Enterococcus*). Since 2019, the emergent pandemic of COVID-19 has taken away everyday life and caused medical collapse worldwide. As most healthcare resources must be used for COVID-19, the AMR plan is forced to change such as re-distribution of economical, medical, educational or human resources.

This Special Issue revisits the past and examines the current status of AMR in Japan and we discuss the future AMR action under COVID-19 pandemic.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPUS / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1
(*General Pharmacology, Toxicology and Pharmaceutics*)

Contact Us

Antibiotics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)